Fenoldopam in Cardiovascular Surgery: A Review

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Acute kidney injury is a serious complication following cardiovascular surgery, resulting in significant inhospital and long-term morbidity and mortality. The mortality rate is distressingly high despite improvements in intensive care and dialytic technology, but survivors experience an acceptable quality of life.

Fenoldopam mesylate is a dopamine A-1 receptor agonist that decreases systemic vascular resistance while increasing renal blood flow. Fenoldopam, used as an antihypertensive drug, has recently demonstrated nephroprotective properties in critically ill patients or during major surgery.

Two recent meta-analyses suggested that fenoldopam reduces the need for renal replacement therapy and mortality in critical ill patients and particularly in those undergoing cardiovascular surgery. In the first meta-analysis of 16 randomised clinical trials for a total of 1290 patients, fenoldopam usage reduced all-cause mortality (81/537 [15.1%] vs 110/581 [18.9%], OR=0.64 [0.45-0.91], p=0.01).

Another meta-analysis was performed in the specific setting of cardiovascular surgery and included 1059 patients (4 trials were performed in vascular surgery and 9 in cardiac surgery). Fenoldopam dosage varied across studies, being always >0.03 μg/kg/min and most often 0.1 μg/kg/min, reaching 0.3 μg/kg/min. Fenoldopam usage reduced the risk of death and the risk of renal replacement therapy (30/528 [5.7%] in the fenoldopam group vs 71/531 [13.4%] in the control arm (OR=0.37 [0.23-0.59], p<0.001).

In this article we review the evidence based medicine to support the use of fenoldopam in patients with or at risk for acute kidney injury and underline the need for a large randomized controlled study to confirm these promising results.
More about this publication?
  • Vascular Disease Prevention publishes reviews as well as original papers to update all those concerned with this topic at the clinical or scientific level. In addition to clinically relevant topics, we consider reviews and original papers dealing with the more scientific aspects of vascular disease prevention. This includes the evaluation of emerging vascular risk factors, research dealing with the pathogenesis of atherosclerosis and the investigation of new treatment options both at the clinical and scientific level (e.g. epidemiology, patient-based studies, experimental models, in vitro experiments or molecular research). Therefore, another function of Vascular Disease Prevention is to bridge the gap between clinical practice and ongoing laboratory-based research.

    In particular, we welcome critical reviews and comments on recent trials. This is a topic that requires regular updates because of the large number of trials published every year.

    Debates are encouraged in the correspondence section of this journal.
    The editorial structure of Vascular Disease Prevention is set up with the aim of dealing with the submitted material as rapidly as possible. Specialist editors will provide a more expert and rapid assessment unlike a more centralized editorial structure.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more